-

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Protect the Value of Your Investment by Voting the WHITE Proxy Card Ahead of the Special Meeting Scheduled for Friday, December 9th

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement recommending stockholders vote on the WHITE proxy card to remove the Company’s Board of Directors (the “Board”) at the upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for Friday, December 9th, 2022:

“It is extremely important that Pasithea stockholders vote their shares on the WHITE proxy card as soon as possible, no matter how many or few shares you own. The Special Meeting is just a few days away and we believe that recent concerning actions taken by Pasithea’s Board — including multiple dilutive acquisitions at stockholders’ expense — underscore why urgent change is needed in the boardroom. By removing the Company’s current directors, we believe Pasithea will finally be positioned to enhance its corporate governance, improve capital allocation and unlock significant value for all stockholders.

Protect the value of your investment TODAY and vote FOR all matters on the WHITE proxy card by telephone, over the Internet, or by signing, dating and returning your WHITE proxy card in the postage-paid envelope provided.”

VOTE THE WHITE PROXY CARD TODAY.

If you have any questions on how to vote your shares on the WHITE proxy card, please contact InvestorCom LLC by email at info@investor-com.com or by telephone at 203-972-9300.

Contacts

For Investors:
Concord Investment Partners Ltd.
David Delaney, 416-951-9214
ddelaney@concordinvestmentpartners.com

InvestorCom LLC
John Grau, 203-972-9300
info@investor-com.com

For Media:
Longacre Square Partners
Charlotte Kiaie / Aaron Rabinovich, 646-386-0091
ckiaie@longacresquare.com / arabinovich@longacresquare.com

CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC

NASDAQ:KTTA

Release Versions

Contacts

For Investors:
Concord Investment Partners Ltd.
David Delaney, 416-951-9214
ddelaney@concordinvestmentpartners.com

InvestorCom LLC
John Grau, 203-972-9300
info@investor-com.com

For Media:
Longacre Square Partners
Charlotte Kiaie / Aaron Rabinovich, 646-386-0091
ckiaie@longacresquare.com / arabinovich@longacresquare.com

More News From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC

Camac Partners Calls on TuSimple to Take Long Overdue Step of Monetizing Remaining Assets and Returning Capital to Shareholders

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (together with its affiliates, “Camac”), a 5.6% shareholder of TuSimple Holdings Inc. (OTCMKTS: TSPH) (“TuSimple” or the “Company”), today released a letter it recently sent to the Company’s Board of Directors (the “Board”). *** May 30, 2024 TuSimple Holdings Inc. Attn: The Board of Directors Dear TuSimple Board of Directors, We are a major independent shareholder of TuSimple, owning approximately 5.6% of the Company. In our view, maintaining the C...

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement in connection with its efforts to remove the Company’s Board of Directors (the “Board”) at the upcoming Special Meeting of Stockholders (...

Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement regarding the Company's recently announced dilutive acquisition of AlloMek Therapeutics, LLC (“AlloMek”). As a reminder, the Investor Group has su...
Back to Newsroom